Literature DB >> 6627074

Succinylcholine apnoea: attempted reversal with anticholinesterases.

D R Bevan, F Donati.   

Abstract

Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. Edrophonium 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained. Repeated doses of edrophonium to 70 mg and neostigmine to 2.5 mg did not antagonize or augment the block. Spontaneous respiration recommenced 200 min after succinylcholine administration. It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627074     DOI: 10.1007/bf03007091

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  11 in total

1.  THE MISMANAGEMENT OF SUXAMETHONIUM APNOEA.

Authors:  M D VICKERS
Journal:  Br J Anaesth       Date:  1963-04       Impact factor: 9.166

Review 2.  Monitoring of neuromuscular function.

Authors:  H H Ali; J J Savarese
Journal:  Anesthesiology       Date:  1976-08       Impact factor: 7.892

3.  Suxamethonium-neostigmine interaction in patients with normal or atypical cholinesterase.

Authors:  A Baraka
Journal:  Br J Anaesth       Date:  1977-05       Impact factor: 9.166

4.  Antagonism of succinylcholine paralysis in a patient with atypical pseudocholinesterase.

Authors:  R D Miller; W C Stevens
Journal:  Anesthesiology       Date:  1972-05       Impact factor: 7.892

5.  Differential effects of myoneural blocking drugs on neuromuscular transmission.

Authors:  N E Williams; S N Webb; T N Calvey
Journal:  Br J Anaesth       Date:  1980-11       Impact factor: 9.166

6.  Twitch depression and train-of-four ratio after antagonism of pancuronium with edrophonium, neostigmine, or pyridostigmine.

Authors:  F Donati; A Ferguson; D R Bevan
Journal:  Anesth Analg       Date:  1983-03       Impact factor: 5.108

7.  Succinylcholine neuromuscular blockade in subjects homozygous for atypical plasma cholinesterase.

Authors:  J Viby-Mogensen
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

8.  Effect of neostigmine and pyridostigmine on the plasma cholinesterase activity.

Authors:  A Baraka; N Wakid; R Mansour; W Haddad
Journal:  Br J Anaesth       Date:  1981-08       Impact factor: 9.166

9.  Train-of-four nerve stimulation in the management of prolonged neuromuscular blockade following succinylcholine.

Authors:  J J Savarese; H H Ali; J D Murphy; C Padget; C M Lee; J Ponitz
Journal:  Anesthesiology       Date:  1975-01       Impact factor: 7.892

10.  Dose relationships of phase II, tachyphylaxis and train-of-four fade in suxamethonium-induced dual neuromuscular block in man.

Authors:  C Lee
Journal:  Br J Anaesth       Date:  1975-08       Impact factor: 9.166

View more
  4 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 2.  Neuromuscular blocking drugs in anaesthesia.

Authors:  F Donati; J C Bevan; D R Bevan
Journal:  Can Anaesth Soc J       Date:  1984-05

3.  Comparison of atracurium and succinylcholine for electroconvulsive therapy in a patient with atypical plasma cholinesterase.

Authors:  D R Hickey; J P O'Connor; F Donati
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

4.  Reversal of succinylcholine induced apnea with an organophosphate scavenging recombinant butyrylcholinesterase.

Authors:  Brian C Geyer; Katherine E Larrimore; Jacquelyn Kilbourne; Latha Kannan; Tsafrir S Mor
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.